Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2008; 29(04): 19-22
DOI: 10.4103/0971-5851.51400
Mini-Review

Role of p53 in transcriptional regulation of proteases in mammals.

Rahul Katara
Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, India
,
N Singh
Department of Biochemistry, J.R..Medical College Gwalior, India
› Author Affiliations
› Further Information
Also available at
  PDF Download Permissions and Reprints

Abstract

p53, besides being a tumor suppressor protein, is a transcription factor with a powerful activation domain. Mutation(s) in this gene is a frequent event in human carcinogenesis. Several of these mutations lead to loss of its function as transcription factor. Proteases are thought to play an important role in tumor invasion and metastasis by degradation of extra cellular matrices and basement membranes. The function of protein-coding genes is carried out by the protein product, it is important to study p53-dependent expression at the protein level. There are many factors which regulate the expression of proteases in the cell, however here in this review we have focused on the p53 gene and its regulatory effect on the expression of proteases.



Publication History

Article published online:
19 November 2021

© 2008. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Turk, D. and Guncar, G. Lysosomal cysteine proteases (cathepsins): promising drug targets. Acta Crystallogr D Biol Crystallogr. 2003;59:203-213.
  • 2 Turk V, Turk B, Guncar G, Turk D, Kos J. Lyso′somal cathepsins: Sturcture, role in antigen processing and presentation and cancer. Adv Enzyme Regul: 2002;42:285-303.
  • 3 Joyce JA, Baruch A, Chehade K, et al. Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell 2004;5:443-453.
  • 4 Kos J, Lah TT. Cysteine proteinases and their endogenous inhibitors : target proteins for prog nosis, diagnosis and therapy in cancer (review). Oncol Rep 1998;5:1349-1346.
  • 5 Foekens JA, Look MP, Bolt-de Vries J, et. al. Cathepsin D in primary breast cancer : prognostic evaluation involving 2810 patients. Br J Cancer 1999;79:300-307.
  • 6 Lah TT, Cercek M, Blejec A, et. al. Cathepsin B, a prognostic indicator in lymph node-negative breast carcinoma patients : comparison with cathepsin D, cathepsin L, and other clinical indicators. Clin Cancer Res 2000;6:578-584.
  • 7 Shengkan Jin, Markus Kalkum, Michael Overholtzer, et. al. CIAP1 and the serine protease HTRA2 are involved in a novel p53-dependent apoptosis pathway in mammals. Genes Dev. 2003;17:359-367.
  • 8 Kawakubo T, Okamoto K, Iwata J, et al. Cathepsin E Prevents Tumor Growth and Metastasis by Catalyzing the Proteolytic Release of Soluble TRAIL from Tumor Cell Surface. Cancer Res. 2007;67(22):10869-78.
  • 9 Junhui Bian and Sun Yi. Transcriptional Activation by p53 of the Human Type IV Collagenase (Gelatinase A or Matrix Metalloproteinase 2) Promoter. MCB. 1997;17:6330-6338.
  • 10 Sun Y, Cheung JM, Martel-Pelletier J, et. al. Wild type and mutant p53 differentially regulate the gene expression of human collagenase-3 (hMMP-13). J Biol Chem. 2000;14:275(15):11327-32.
  • 11 Sun Y, Zeng XR, Wenger L, Firestein GS, Cheung HS, P53 down-regulates matrix metalloproteinase-1 by targeting the communications between AP-1 and the basal transcription complex. J Cell Biochem 2004; 15:258-69.
  • 12 Liu J, Zhan M, Hannay JAF. Wild-type p53 inhibits nuclear factor-B-induced matrix metalloproteinase-9 promotor activation: Implications of soft tissue sarcoma growth and metastasis. Mol Cancer Res) 2006;4:803-810.
  • 13 Meyer E, Vollmer JY, Bovey R, Stamenkovic I. Matrix metalloproteinases 9 and 10 inhibit protein kinase Cpotentiated, p53-mediated apoptosis. Cancer Res 2005;65:4261-4272.
  • 14 Turk V, Turk B, Guncar G, Turk D, Kos J. L.yso′somal cathepsins: Sturcture, role in antigen processing and presentation and cancer. Adv Enzyme Regul: 2002;42:285-303.
  • 15 Hecht M, von Metzler I, Sack K. Interactions of myeloma cells with osteoclasts promote tumour expansion and bone degradation through activation of a complex signalling network and upregulation of cathepsin K, matrix metalloproteinases (MMPs) and urokinase plasminogen activator (uPA) Exp. Cell Res. 2008;314(5):1082-1093.
  • 16 Losch V, Schindl M. Kohlberger P. et. al. Cathepsin D in ovarian cancer: prognostic value and correlation with p53 expression and microvessel density. Gynecol Oncol 2004;92:545-552.
  • 17 Wu GS, Saftig P, Peters C and El-Diery WS Potential role for Cathepsin D in p53 -dependent tumor suppression and chemosensitivity. Oncogene, 1998;16:2177-83.
  • 18 Lewis BC Klimstra DS, Socci ND et. al. The Absence of p53 Promotes Metastasis in a Novel Somatic Mouse Model for Hepatocellular Carcinoma Mol. Cell. Biol.2005;25:1228-1237
  • 19 Inga, A., Storici, F., Darden, T. A.& Resnick, M. A. Differential Transactivation by the p53 Transcription Factor Is Highly Dependent on p53 Level and Promoter Target Sequence Mol. Cell. Biol.2002;22:8612-25.
  • 20 Bourdon J-C Deguin-Chambon V, Lelong JC et. al. Further characterization of the p53 responsive element- identification of new candidate genes for trans-activation by p53. Oncogene 1997;14:85-94.
  • 21 Levine, A. J. p53, the cellular gatekeeper for growth and division Cell 1997;88:323-331.
  • 22 Lo, P. K., Chen, J. Y., Tang, P. P. et. al. Identification of a Mouse Thiamine Transporter Gene as a Direct Transcriptional Target for p53FNx01 J. Biol. Chem. 2001;276:37186-93.